Risk stratification and medical therapy of pulmonary arterial hypertension

• Verfasst von: Galiè, Nazzareno [VerfasserIn]
• Verfasst von: Grünig, Ekkehard [VerfasserIn]
• Titel: Risk stratification and medical therapy of pulmonary arterial hypertension
• Verf.angabe: Nazzareno Galiè, Richard N. Channick, Robert P. Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R. Preston, Tomas Pulido, Zeenat Safdar, Yuichi Tamura and Vallerie V. McLaughlin
• E-Jahr: 2019
• Jahr: January 24, 2019
• Umfang: 11 S.
• Fussnoten: Number 6 in the series “Proceedings of the 6th World Symposium on Pulmonary Hypertension” edited by N. Galiè, V.V. McLaughlin, L.J. Rubin and G. Simonneau ; Gesehen am 28.10.2019
• Titel Quelle: Enthalten in: European respiratory journal
• Ort Quelle: Lausanne : ERS, 1988
• Jahr Quelle: 2019
• Band/Heft Quelle: 53(2019,1) Artikel-Nummer 1801889, 11 Seiten
• ISSN Quelle: 1399-3003
• DOI: doi:10.1183/13993003.01889-2018
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 168003474X

Abstract

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy. - Tweetable abstract @ERSpublications - click to tweetState of the art and research perspectives on medical therapy of pulmonary arterial hypertension, including treatment algorithm http://ow.ly/4UkJ30md5GS